Targeted therapies in sarcomas: Challenging the challenge

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Liberal, Juan Martin ^a   Lagares Tena, Laura ^a   Sainz Jaspeado, Miguel ^a   Mateo Lozano, Silvia ^b   Garcia Del Muro, Xavier ^a   Tirado, Oscar M ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CIXUTUMUMAB; CRIZOTINIB; DASATINIB; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; ONCOLYTIC ADENOVIRUS; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; VIROTHERAPY AGENT;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CHROMOSOME TRANSLOCATION; DRUG EFFICACY; GENE TARGETING; HUMAN; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SARCOMA;

EID: 84864529527     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/626094     Document Type: Review

References (132)

1. Italiano A., Mathoulin-Pelissier S., Le Cesne A., Terrier P., Bonvalot S., Collin F., Michels J. J., Blay J. Y., Coindre J. M., Bui B., Trends in survival for patients with metastatic soft-tissue sarcoma Cancer 2011 117 5 1049 1054
2. Casali P. G., Blay J. Y., ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology 2010 21 supplement 5 v198 v203
3. Wardelmann E., Schildhaus H. U., Merkelbach-Bruse S., Hartmann W., Reichardt P., Hohenberger P., Bttner R., Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies Annals of Oncology 2010 21 7 vii265 vii269
4. Jain R. K., Duda D. G., Clark J. W., Loeffler J. S., Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature Clinical Practice Oncology 2006 3 1 24 40 (Pubitemid 43108832)
5. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress Endocrine Reviews 2004 25 4 581 611 (Pubitemid 39099316)
6. Ferrara N., VEGF-A: a critical regulator of blood vessel growth European Cytokine Network 2009 20 4 158 163
7. Nagy J. A., Dvorak A. M., Dvorak H. F., VEGF-A and the induction of pathological angiogenesis Annual Review of Pathology 2007 2 251 275 (Pubitemid 46448066)
8. Potti A., Ganti A. K., Tendulkar K., Sholes K., Chitajallu S., Koch M., Kargas S., Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma Journal of Cancer Research and Clinical Oncology 2004 130 1 52 56 (Pubitemid 38161248)
9. Graeven U., Andre N., Achilles E., Zornig C., Schmiegel W., Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma Journal of Cancer Research and Clinical Oncology 1999 125 10 577 581 (Pubitemid 29434883)
10. Chao C., Al-Saleem T., Brooks J. J., Rogatko A., Kraybill W. G., Eisenberg B., Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade Annals of Surgical Oncology 2001 8 3 260 267 (Pubitemid 32294808)
11. Iyoda A., Hiroshima K., Baba M., Fujisawa T., Yusa T., Ohwada H., Expression of vascular endothelial growth factor in thoracic sarcomas Annals of Thoracic Surgery 2001 71 5 1635 1639
12. Shintani K., Matsumine A., Kusuzaki K., Matsubara T., Satonaka H., Wakabayashi T., Hoki Y., Uchida A., Expression of hypoxia-inducible factor (HIF)-1 as a biomarker of outcome in soft-tissue sarcomas Virchows Archiv 2006 449 6 673 681 (Pubitemid 44832639)
13. Comandone A., Boglione A., Berardengo E., Microvessel density (MVD) as a marker of neoangiogenesis: prognostic significance in correlation to grading and stage in adult soft tissue sarcoma (STS) of the extremities. A perspective study Proceedings of the American Society of Clinical Oncology 2003 22, abstract 3303
14. West C. C., Brown N. J., Mangham D. C., Grimer R. J., Reed M. W. R., Microvessel density does not predict outcome in high grade soft tissue sarcoma European Journal of Surgical Oncology 2005 31 10 1198 1205 (Pubitemid 41819208)
15. Saenz N. C., Heslin M. J., Adsay V., Lewis J. J., Leung D. H., LaQuaglia M. P., Brennan M. F., Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas Annals of Surgical Oncology 1998 5 1 48 53 (Pubitemid 28328058)
16. Yudoh K., Kanamori M., Ohmori K., Yasuda T., Aoki M., Kimura T., Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas British Journal of Cancer 2001 84 12 1610 1615 (Pubitemid 32612491)
17. Stacchiotti S., Tamborini E., Marrari A., Brich S., Rota S. A., Orsenigo M., Crippa F., Morosi C., Gronchi A., Pierotti M. A., Casali P. G., Pilotti S., Response to sunitinib malate in advanced alveolar soft part sarcoma Clinical Cancer Research 2009 15 3 1096 1104
18. George S., Merriam P., Maki R. G., Van Den Abbeele A. D., Yap J. T., Akhurst T., Harmon D. C., Bhuchar G., O'Mara M. M., D'Adamo D. R., Morgan J., Schwartz G. K., Wagner A. J., Butrynski J. E., Demetri G. D., Keohan M. L., Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas Journal of Clinical Oncology 2009 27 19 3154 3160
19. Mahmood S. T., Agresta S., Vigil C., Zhao X., Han G., D'Amato G., Calitri C. E., Dean M., Garrett C., Schell M. J., Antonia S., Chiappori A., Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma International Journal of Cancer 2010 129 1963 1969
20. Hensley M. L., Sill M. W., Scribner D. R., Brown J., DeBernardo R. L., Hartenbach E. M., McCourt C. K., Bosscher J. R., Gehrig P. A., Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Gynecologic Oncology 2009 115 3 460 465
21. Lu X., Tang X., Guo W., Ren T., Zhao H., Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway Journal of Surgical Oncology 2010 102 7 821 826
22. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., Bottos A., Gammaitoni L., Migliardi G., Camussi G., Alberghini M., Torchio B., Ferrari S., Bussolino F., Fagioli F., Picci P., Aglietta M., Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways Molecular Cancer 2009 8, article 118
23. Maruwge W., D'Arcy P., Folin A., Brnjic S, Wejde J, Davis A, Erlandsson F, Bergh J, Brodin B., Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling OncoTargets and Therapy 2008 1 67 78
24. Peng C. L., Guo W., Ji T., Ren T., Yang Y., Li D. S., Qu H. Y., Li X., Tang S., Yan T. Q., Tang X. D., Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway Cancer Biology and Therapy 2009 8 18 1729 1736
25. Ambrosini G., Cheema H. S., Seelman S., Teed A., Sambol E. B., Singer S., Schwartz G. K., Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells Molecular Cancer Therapeutics 2008 7 4 890 896
26. Ardavanis A., Doufexis D., Kountourakis P., Rigatos G., A Kaposi's sarcoma complete clinical response after sorafenib administration Annals of Oncology 2008 19 9 1658 1659
27. Basso U., Brunello A., Bertuzzi A., Santoro A., Sorafenib is active on lung metastases from synovial sarcoma Annals of Oncology 2009 20 2 386 387
28. Maki R. G., D'Adamo D. R., Keohan M. L., Saulle M., Schuetze S. M., Undevia S. D., Livingston M. B., Cooney M. M., Hensley M. L., Mita M. M., Takimoto C. H., Kraft A. S., Elias A. D., Brockstein B., Blachre N. E., Edgar M. A., Schwartz L. H., Qin L. X., Antonescu C. R., Schwartz G. K., Phase II study of sorafenib in patients with metastatic or recurrent sarcomas Journal of Clinical Oncology 2009 27 19 3133 3140
29. Grignani G., Palmerini E., Dileo P., Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M., A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an ItalianSarcoma Group study Annals of Oncology 2012 23 508 516
30. Von Mehren M., Rankin C., Goldblum J. R., Demetri G. D., Bramwell V., Ryan C. W., Borden E., Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas Cancer 2012 118 770 776
31. Pacey S., Ratain M. J., Flaherty K. T., Kaye S. B., Cupit L., Rowinsky E. K., Xia C., O'Dwyer P. J., Judson I. R., Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial Investigational New Drugs 2011 29 3 481 488
32. Sleijfer S., Ray-Coquard I., Papai Z., Le Cesne A., Scurr M., Schffski P., Collin F., Pandite L., Marreaud S., De Brauwer A., Van Glabbeke M., Verweij J., Blay J. Y., Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043) Journal of Clinical Oncology 2009 27 19 3126 3132
33. Van-der-Graaf W, Blay J., Chawla S. P., PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapyan EORTC STBSG Global Network Study (EORTC 62072) Journal of Clinical Oncology 2011 29, abstract LBA10002
34. Shor A. C., Keschman E. A., Lee F. Y., Muro-Cacho C., Letson G. D., Trent J. C., Pledger W. J., Jove R., Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival Cancer Research 2007 67 6 2800 2808 (Pubitemid 46548969)
35. Timeus F., Crescenzio N., Fandi A., Doria A., Foglia L., di Montezemolo L. C., In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines Oncology Reports 2008 19 2 353 359 (Pubitemid 351176094)
36. Hingorani P., Zhang W., Gorlick R., Kolb E. A., Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo Clinical Cancer Research 2009 15 10 3416 3422
37. Schrage Y. M., Briaire-de Bruijn I. H., De Miranda N. F. C. C., Van Oosterwijk J., Taminiau A. H. M., Van Wezel T., Hogendoorn P. C. W., Bovée J. V. M. G., Kinome profiling of chondrosarcoma reveals Src-pathway activity and dasatinib as option for treatment Cancer Research 2009 69 15 6216 6222
38. Dalal S., Berry A. M., Cullinane C. J., Mangham D. C., Grimer R., Lewis I. J., Johnston C., Laurence V., Burchill S. A., Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma Family Clinical Cancer Research 2005 11 6 2364 2378 (Pubitemid 40490198)
39. Ferrario A., Gomer C. J., Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model Journal of Environmental Pathology, Toxicology and Oncology 2006 25 251 259 (Pubitemid 43341245)
40. Vistica D. T., Hollingshead M., Borgel S. D., Kenney S., Stockwin L. H., Raffeld M., Schrump D. S., Burkett S., Stone G., Butcher D. O., Shoemaker R. H., Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy Journal of Pediatric Hematology/Oncology 2009 31 8 561 570
41. Myers A. L., Williams R. F., Ng C. Y., Hartwich J. E., Davidoff A. M., Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation Journal of Pediatric Surgery 2010 45 6 1080 1085
42. Okada Y., Akisue T., Hara H., Kishimoto K., Kawamoto T., Imabori M., Kishimoto S. I., Fukase N., Onishi Y., Kurosaka M., The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model Anticancer Research 2010 30 9 3391 3395
43. D'Adamo D. R., Anderson S. E., Albritton K., Yamada J., Riedel E., Scheu K., Schwartz G. K., Chen H., Maki R. G., Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas Journal of Clinical Oncology 2005 23 28 7135 7142
44. Verschraegen C. F., Arias-Pulido H., Lee S. J., Movva S., Cerilli L. A., Eberhardt S., Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T., Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen Annals of Oncology 2011 23 785 790
45. Gorlick R., Anderson P., Andrulis I., Arndt C., Beardsley G. P., Bernstein M., Bridge J., Cheung N. K., Dome J. S., Ebb D., Gardner T., Gebhardt M., Grier H., Hansen M., Healey J., Helman L., Hock J., Houghton J., Houghton P., Huvos A., Khanna C., Kieran M., Kleinerman E., Ladanyi M., Lau C., Malkin D., Marina N., Meltzer P., Meyers P., Schofield D., Schwartz C., Smith M. A., Toretsky J., Tsokos M., Wexler L., Wigginton J., Withrow S., Schoenfeldt M., Anderson B., Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting Summary Clinical Cancer Research 2003 9 15 5442 5453 (Pubitemid 37499462)
46. Prieur A., Tirode F., Cohen P., Delattre O., EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3 Molecular and Cellular Biology 2004 24 16 7275 7283 (Pubitemid 39014452)
47. Khan J., Bittner M. L., Saal L. H., Teichmann U., Azorsa D. O., Gooden G. C., Pavan W. J., Trent J. M., Meltzer P. S., cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene Proceedings of the National Academy of Sciences of the United States of America 1999 96 23 13264 13269
48. Ayalon D., Glaser T., Werner H., Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein Growth Hormone and IGF Research 2001 11 5 289 297
49. Karnieli E., Werner H., Rauscher F. J., Benjamin L. E., Leroith D., The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein Journal of Biological Chemistry 1996 271 32 19304 19309 (Pubitemid 26271599)
50. Finkeltov I., Kuhn S., Glaser T., Idelman G., Wright J. J., Roberts C. T., Werner H., Transcriptional regulation of IGF-I receptor gene expression by novel isoforms of the EWS-WT1 fusion protein Oncogene 2002 21 12 1890 1898 (Pubitemid 34259192)
51. Werner H., Idelman G., Rubinstein M., Pattee P., Nagalla S. R., Roberts C. T., A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene Cancer Letters 2007 247 1-2 84 90 (Pubitemid 44959411)
52. Pedone P. V., Tirabosco R., Cavazzana A. O., Ungaro P., Basso G., Luksch R., Carli M., Bruni C. B., Frunzio R., Riccio A., Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors Human Molecular Genetics 1994 3 7 1117 1121 (Pubitemid 24211956)
53. Scrable H., Cavenee W., Ghavimi F., Lovell M., Morgan K., Sapienza C., A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting Proceedings of the National Academy of Sciences of the United States of America 1989 86 19 7480 7484 (Pubitemid 19254480)
54. Visser M., Sijmons C., Bras J., Arceci R. J., Godfried M., Valentijn L. J., Vote P. A., Baas F., Allelotype of pediatric rhabdomyosarcoma Oncogene 1997 15 11 1309 1314 (Pubitemid 27429747)
55. Zhan S., Shapiro D. N., Helman L. J., Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma Journal of Clinical Investigation 1994 94 1 445 448 (Pubitemid 24218124)
56. Anderson J., Gordon A., Pritchard-Jones K., Genes, chromosomes, and rhabdomyosarcoma Genes Chromosomes Cancer 1999 26 275 285
57. Sun Y., Gao D., Liu Y., Huang J., Lessnick S., Tanaka S., IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1 Oncogene 2006 25 7 1042 1052 (Pubitemid 43277012)
58. De Bruijn D. R. H., Allander S. V., Van Dijk A. H. A., Willemse M. P., Thijssen J., Van Groningen J. J. M., Meltzer P. S., Van Kessel A. G., The synovial sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation Cancer Research 2006 66 19 9474 9482 (Pubitemid 44623645)
59. Shapiro D. N., Jones B. G., Shapiro L. H., Dias P., Houghton P. J., Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma Journal of Clinical Investigation 1994 94 3 1235 1242 (Pubitemid 24286468)
60. Scotlandi K., Avnet S., Benini S., Manara M. C., Serra M., Cerisano V., Perdichizzi S., Lollini P. L., De Giovanni C., Landuzzi L., Picci P., Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells International Journal of Cancer 2002 101 1 11 16 (Pubitemid 34832991)
61. Scotlandi K., Benini S., Nanni P., Lollini P. L., Nicoletti G., Landuzzi L., Serra M., Manara M. C., Picci P., Baldini N., Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice Cancer Research 1998 58 18 4127 4131 (Pubitemid 28440569)
62. Anders Kolb E., Gorlick R., Houghton P. J., Morton C. L., Lock R., Carol H., Patrick Reynolds C., Maris J. M., Keir S. T., Billups C. A., Smith M. A., Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program Pediatric Blood and Cancer 2008 50 6 1190 1197
63. Kalebic T., Tsokos M., Helman L. J., In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34(cdc2) Cancer Research 1994 54 21 5531 5534
64. Scotlandi K., Manara M. C., Nicoletti G., Lollini P. L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., Garca-Echeverra C., Hofmann F., Picci P., Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors Cancer Research 2005 65 9 3868 3876 (Pubitemid 40616368)
65. Martins A. S., Mackintosh C., Herrero Martn D., Campos M., Hernndez T., Ordez J. L., De Alava E., Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor Clinical Cancer Research 2006 12 11 I 3532 3540
66. Manara M. C., Landuzzi L., Nanni P., Nicoletti G., Zambelli D., Lollini P. L., Nanni C., Hofmann F., Garca-Echeverra C., Picci P., Scotlandi K., Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma Clinical Cancer Research 2007 13 4 1322 1330 (Pubitemid 46424074)
67. Cao L., Yu Y., Darko I., Currier D., Mayeenuddin L. H., Wan X., Khanna C., Helman L. J., Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody Cancer Research 2008 68 19 8039 8048
68. Tolcher A. W., Sarantopoulos J., Patnaik A., Papadopoulos K., Lin C. C., Rodon J., Murphy B., Roth B., McCaffery I., Gorski K. S., Kaiser B., Zhu M., Deng H., Friberg G., Puzanov I., Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 Journal of Clinical Oncology 2009 27 34 5800 5807
69. Olmos D., Postel-Vinay S., Molife L. R., Okuno S. H., Schuetze S. M., Paccagnella M. L., Batzel G. N., Yin D., Pritchard-Jones K., Judson I., Worden F. P., Gualberto A., Scurr M., de Bono J. S., Haluska P., Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study The Lancet Oncology 2010 11 2 129 135
70. Schoffski P., Adkins D., Blay J., Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors Journal of Clinical Oncology 2011 29, abstract 10004
71. Scotlandi K., Manara M. C., Nicoletti G., Lollini P. L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., Garca-Echeverra C., Hofmann F., Picci P., Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors Cancer Research 2005 65 9 3868 3876 (Pubitemid 40616368)
72. Martins A. S., Mackintosh C., Herrero Martn D., Campos M., Hernndez T., Ordez J. L., De Alava E., Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor Clinical Cancer Research 2006 12 11 I 3532 3540
73. Manara M. C., Landuzzi L., Nanni P., Nicoletti G., Zambelli D., Lollini P. L., Nanni C., Hofmann F., Garca-Echeverra C., Picci P., Scotlandi K., Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma Clinical Cancer Research 2007 13 4 1322 1330 (Pubitemid 46424074)
74. Sabbatini P., Rowand J. L., Groy A., Korenchuk S., Liu Q., Atkins C., Dumble M., Yang J., Anderson K., Wilson B. J., Emmitte K. A., Rabindran S. K., Kumar R., Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase Clinical Cancer Research 2009 15 9 3058 3067
75. Sabbatini P., Korenchuk S., Rowand J. L., Groy A., Liu Q., Leperi D., Atkins C., Dumble M., Yang J., Anderson K., Kruger R. G., Gontarek R. R., Maksimchuk K. R., Suravajjala S., Lapierre R. R., Shotwell J. B., Wilson J. W., Chamberlain S. D., Rabindran S. K., Kumar R., GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers Molecular Cancer Therapeutics 2009 8 10 2811 2820
76. Huang F., Greer A., Hurlburt W., Han X., Hafezi R., Wittenberg G. M., Reeves K., Chen J., Robinson D., Li A., Lee F. Y., Gottardis M. M., Clark E., Helman L., Attar R. M., Dongre A., Carboni J. M., The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors Cancer Research 2009 69 1 161 170
77. Friedrichs N., Kchler J., Endl E., Koch A., Czerwitzki J., Wurst P., Metzger D., Schulte J. H., Holst M. I., Heukamp L. C., Larsson O., Tanaka S., Kawai A., Wardelmann E., Buettner R., Pietsch T., Hartmann W., Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma Journal of Pathology 2008 216 4 428 439
78. Duan Z., Choy E., Harmon D., Yang C., Ryu K., Schwab J., Mankin H., Hornicek F. J., Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines Molecular Cancer Therapeutics 2009 8 8 2122 2130
79. Wan X., Helman L. J., The biology behind mTOR inhibition in sarcoma Oncologist 2007 12 8 1007 1018 (Pubitemid 47359144)
80. Samani A. A., Yakar S., LeRoith D., Brodt P., The role of the IGF system in cancer growth and metastasis: overview and recent insights Endocrine Reviews 2007 28 1 20 47 (Pubitemid 46220849)
81. Xie Y., Skytting B., Nilsson G., Brodin B., Larsson O., Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype Cancer Research 1999 59 15 3588 3591 (Pubitemid 29381857)
82. Girnita L., Girnita A., Wang M., Meis-Kindblom J. M., Kindblom L. G., Larsson O., A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells Oncogene 2000 19 37 4298 4301
83. Hughes D. P. M., Thomas D. G., Giordano T. J., Baker L. H., McDonagh K. T., Cell surface expression of epidermal growth factor receptor and her-2 with nuclear expression of Her-4 in primary osteosarcoma Cancer Research 2004 64 6 2047 2053 (Pubitemid 38339452)
84. Ganti R., Skapek S. X., Zhang J., Fuller C. E., Wu J., Billups C. A., Breitfeld P. P., Dalton J. D., Meyer W. H., Khoury J. D., Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma Modern Pathology 2006 19 9 1213 1220 (Pubitemid 44268191)
85. Sampson J. R., Therapeutic targeting of mTOR in tuberous sclerosis Biochemical Society Transactions 2009 37 1 259 264
86. Umeoka S., Koyama T., Miki Y., Akai M., Tsutsui K., Togashi K., Pictorial review of tuberous sclerosis in various organs Radiographics 2008 28 7, article e32
87. Boyd K. P., Korf B. R., Theos A., Neurofibromatosis type 1 Journal of the American Academy of Dermatology 2009 61 1 1 14
88. Katz D., Lazar A., Lev D., Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways Expert Reviews in Molecular Medicine 2009 11 e30
89. Mateo-Lozano S., Gokhale P. C., Soldatenkov V., Dritschilo A., Tirado O. M., Notario V., Combination therapy targeting EWS/FLI-1 oncogene induces apoptosis of Ewings sarcoma cells in vitro and inhibits tumor growth in vivo Clinical Cancer Research 2006 12 6781 6790
90. Houghton P. J., Morton C. L., Gorlick R., Lock R. B., Carol H., Reynolds C. P., Kang M. H., Maris J. M., Keir S. T., Kolb E. A., Wu J., Wozniak A. W., Billups C. A., Rubinstein L., Smith M. A., Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program Molecular Cancer Therapeutics 2010 9 1 101 112
91. Schuetze S., Zhao L., Chugh R., Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma Journal of Clinical Oncology 2011 29, Abstract 10003
92. Dudkin L., Dilling M. B., Cheshire P. J., Harwood F. C., Hollingshead M., Arbuck S. G., Travis R., Sausville E. A., Houghton P. J., Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clinical Cancer Research 2001 7 6 1758 1764 (Pubitemid 32708646)
93. Wan X., Shen N., Mendoza A., Khanna C., Helman L. J., CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1 /VEGF signaling Neoplasia 2006 8 5 394 401 (Pubitemid 43830746)
94. Okuno S., Bailey H., Mahoney M. R., Adkins D., Maples W., Fitch T., Ettinger D., Erlichman C., Sarkaria J. N., A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the mayo phase 2 Consortium (P2C) Cancer 2011 117 15 3468 3475
95. Geoerger B., Kieran M. W., Grupp S., Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma Journal of Clinical Oncology 2010 28 15S, abstract 9541
96. Hernando E., Charytonowicz E., Dudas M. E., Menendez S., Matushansky I., Mills J., Socci N. D., Behrendt N., Ma L., Maki R. G., Pandolfi P. P., Cordon-Cardo C., The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nature Medicine 2007 13 6 748 753 (Pubitemid 46889749)
97. Richter S., Pink D., Hohenberger P., Multicenter, triplearm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST Journal of Clinical Oncology 2010 28 15S, abstract 10038
98. Squillace R. M., Miller D., Cookson M., Wardwell S. D., Moran L., Clapham D., Wang F., Clackson T., Rivera V. M., Antitumor activity of ridaforolimus and potential cell cycle determinants of sensitivity in sarcoma and endometrial cancer models Molecular Cancer Therapeutics 2011 10 1959 1968
99. Chawla S. P., Staddon A. P., Baker L. H., Schuetze S. M., Tolcher A. W., DAmato G. Z., Blay J. Y., Mita M. M., Sankhala K. K., Berk L., Rivera V. M., Clackson T., Loewy J. W., Haluska F. G., Demetri G. D., Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas Journal of Clinical Oncology 2012 30 1 78 84
100. Chawla S. P., Blay J., Ray-Coquard I. L., Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) Annals of Oncology 2011 29, abstract 10005
101. Wagner A. J., Malinowska-Kolodziej I., Morgan J. A., Qin W., Fletcher C. D. M., Vena N., Ligon A. H., Antonescu C. R., Ramaiya N. H., Demetri G. D., Kwiatkowski D. J., Maki R. G., Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors Journal of Clinical Oncology 2010 28 5 835 840
102. Italiano A., Delcambre C., Hostein I., Cazeau A. L., Marty M., Avril A., Coindre J. M., Bui B., Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa perivascular epithelioid cell tumors (PEComas) are rare Annals of Oncology 2010 21 5 1135 1137
103. Subbiah V., Trent J. C., Kurzrock R., Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors Journal of Clinical Oncology 2010 28 24 e415
104. Sinz-Jaspeado M., Martin-Liberal J., Lagares-Tena L., Mateo-Lozano S., Garcia-del-Muro X., Tirado O. M., Caveolin-1 in sarcomas: friend or foe? Oncotarget 2011 2 305 312
105. McArthur G. A., Demetri G. D., Van Oosterom A., Heinrich M. C., Debiec-Rychter M., Corless C. L., Nikolova Z., Dimitrijevic S., Fletcher J. A., Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225 Journal of Clinical Oncology 2005 23 4 866 873 (Pubitemid 46224187)
106. Rutkowski P., Van Glabbeke M., Rankin C. J., Ruka W., Rubin B. P., Debiec-Rychter M., Lazar A., Gelderblom H., Sciot R., Lopez-Terrada D., Hohenberger P., Van Oosterom A. T., Schuetze S. M., Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials Journal of Clinical Oncology 2010 28 10 1772 1779
107. Goldberg J. D. G., Choy E., Rosen L., Preliminary results from a phase II study of ARQ197 in patients with microphthalmia transcription family (MiT)-associated tumors Journal of Clinical Oncology 2009 27, abstract 10502
108. Erkizan H. V., Kong Y., Merchant M., Schlottmann S., Barber-Rotenberg J. S., Yuan L., Abaan O. D., Chou T. H., Dakshanamurthy S., Brown M. L., Ren A., Toretsky J. A., A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma Nature Medicine 2009 15 7 750 756
109. Breitbach C. J., Burke J., Jonker D., Stephenson J., Haas A. R., Chow L. Q., Nieva J., Hwang T. H., Moon A., Patt R., Pelusio A., Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH., Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Nature 2011 477 99 102
110. Li G., Kawashima H., Ogose A., Ariizumi T., Xu Y., Hotta T., Urata Y., Fujiwara T., Endo N., Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus Journal of Cancer Research and Clinical Oncology 2011 137 6 1037 1051
111. Kurmasheva R. T., Dudkin L., Billups C., Debelenko L. V., Morton C. L., Houghton P. J., The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma Cancer Research 2009 69 19 7662 7671
112. Huang F., Greer A., Hurlburt W., Han X., Hafezi R., Wittenberg G. M., Reeves K., Chen J., Robinson D., Li A., Lee F. Y., Gottardis M. M., Clark E., Helman L., Attar R. M., Dongre A., Carboni J. M., The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors Cancer Research 2009 69 1 161 170
113. Martins A. S., Ordoez J. L., Garca-Snchez A., Herrero D., Sevillano V., Osuna D., Mackintosh C., Caballero G., Otero A. P., Poremba C., Madoz-Grpide J., De Alava E., A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study Cancer Research 2008 68 15 6260 6270
114. Quek R., Wang Q., Morgan J. A., Shapiro G. I., Butrynski J. E., Ramaiya N., Huftalen T., Jederlinic N., Manola J., Wagner A. J., Demetri G. D., George S., Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors Clinical Cancer Research 2011 17 4 871 879
115. Naing A., Kurzrock R., Burger A., Gupta S., Lei X., Busaidy N., Hong D., Chen H. X., Doyle L. A., Heilbrun L. K., Rohren E, Ng C, Chandhasin C, Lorusso PC, Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer Clinical Cancer Research 2011 17 6052 6060
116. Butrynski J. E., D'Adamo D. R., Hornick J. L., Cin P. D., Antonescu C. R., Jhanwar S. C., Ladanyi M., Capelletti M., Rodig S. J., Ramaiya N., Kwak E. L., Clark J. W., Wilner K. D., Christensen J. G., Jnne P. A., Maki R. G., Demetri G. D., Shapiro G. I., Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor New England Journal of Medicine 2010 363 18 1727 1733
117. Zibat A., Missiaglia E., Rosenberger A., Pritchard-Jones K., Shipley J., Hahn H., Fulda S., Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma Oncogene 2010 29 48 6323 6330
118. Hirotsu M., Setoguchi T., Sasaki H., Matsunoshita Y., Gao H., Nagao H., Kunigou O., Komiya S., Smoothened as a new therapeutic target for human osteosarcoma Molecular Cancer 2010 9, article 5
119. Tiet T. D., Hopyan S., Nadesan P., Gokgoz N., Poon R., Lin A. C., Yan T., Andrulis I. L., Alman B. A., Wunder J. S., Constitutive Hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation American Journal of Pathology 2006 168 1 321 330 (Pubitemid 43062583)
120. Joo J., Christensen L., Warner K., States L., Kang H. G., Vo K., Lawlor E. R., May W. A., GLI1 is a central mediator of EWS/FLI1 signaling in Ewing Tumors PLoS ONE 2009 4 10
121. Beauchamp E., Bulut G., Abaan O., Chen K., Merchant A., Matsui W., Endo Y., Rubin J. S., Toretsky J., ren A., GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein Journal of Biological Chemistry 2009 284 14 9074 9082
122. Roma J., Masi A., Revents J., De Toledo J. S., Gallego S., Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro Clinical Cancer Research 2011 17 3 505 513
123. Tanaka M., Setoguchi T., Hirotsu M., Gao H., Sasaki H., Matsunoshita Y., Komiya S., Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation British Journal of Cancer 2009 100 12 1957 1965
124. Sampson E. R., Amin V., Schwarz E. M., O'Keefe R. J., Rosier R. N., The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy Journal of Orthopaedic Research 2011 29 4 623 632
125. Su L., Cheng H., Sampaio A. V., Nielsen T. O., Underhill T. M., EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor Oncogene 2010 29 30 4352 4361
126. Hrzenjak A., Moinfar F., Kremser M. L., Strohmeier B., Petru E., Zatloukal K., Denk H., Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo Molecular Cancer 2010 9, article 49
127. Nielsen T. O., Nguyen A., Su L., Campbell B., Poulin N. M., Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma Sarcoma 2009 2009
128. Lubieniecka J. M., De Bruijn D. R. H., Su L., Van Dijk A. H. A., Subramanian S., Van De Rijn M., Poulin N., Van Kessel A. G., Nielsen T. O., Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma Cancer Research 2008 68 11 4303 4310
129. Manara M. C., Nicoletti G., Zambelli D., Ventura S., Guerzoni C., Landuzzi L., Lollini P. L., Maira S. M., Garca-Echeverra C., Mercuri M., Picci P., Scotlandi K., NVP-BEZ235 as a new therapeutic option for sarcomas Clinical Cancer Research 2010 16 2 530 540
130. Mller C. R., Paulsen E. B., Noordhuis P., Pedeutour F., Ster G., Myklebost O., Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A International Journal of Cancer 2007 121 1 199 205 (Pubitemid 46753868)
131. Brassesco M. S., Cortez M. A., Valera E. T., Engel E. E., Nogueira-Barbosa M. H., Becker A. P., Scrideli C. A., Tone L. G., Cryptic SYT/SXX1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive BCL2 overexpression Cancer Genetics and Cytogenetics 2010 196 2 189 193
132. Tirado O. M., Mateo-Lozano S., Notario V., Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo Cancer Research 2005 65 20 9320 9327 (Pubitemid 41507999)